McKesson's oncology and GLP-1 strength drives raised guidance despite pricing headwinds
Raised fiscal 2027 guidance on broad-based growth McKesson raised full-year adjusted EPS guidance to $44.20–$45.00, implying 13–15% growth, after first-quarter results beat expectations. Three of four segments posted double-digit growth, led by oncology and prescription technology. This directly lifts investor expectations for future profits, pushing the stock up.
This is the core new positive event that answers why MCK is moving right now.
Oncology and GLP-1 distribution surge Oncology & Multispecialty revenue jumped 33% to $14.2 billion with operating profit up 41%, while GLP-1 distribution revenue reached $15 billion, up 24% year over year. These high-growth areas are becoming a bigger part of McKesson's business, supporting higher profits and a higher stock price.
It explains the fundamental growth engine behind the raised guidance and investor optimism.
Acquisition of Precision Medicine Group for $2.25 billion McKesson agreed to buy Precision Medicine Group, a clinical research and biopharma services provider, for about $2.25 billion. The deal expands its higher-growth oncology and specialty services. While modest in size, it signals continued strategic investment that could add future earnings, supporting the stock.
This is a new strategic move that investors are evaluating as a driver of future growth.
Branded drug price cuts and integration risks persist Price reductions by branded manufacturers cut North American Pharmaceutical revenue growth by about 3 percentage points and are expected to continue through fiscal 2027. Acquisition integration and unpredictable Prescription Technology Solutions performance also pose risks. These pressures can limit profit growth and weigh on the stock.
It provides the necessary counterweight, showing real headwinds that could offset positive drivers.